Evidence map›Paper›PMID 40566080›Full record

ArticleJournal of clinical medicine2025

Reported Adverse Events in Patients with CF Receiving Treatment with Elexacaftor/Tezacaftor/Ivacaftor: 5 Years Observational Study.

Francesca Lucca, Ilaria Meneghelli, Gloria Tridello, Francesca Buniotto, Giulia Cucchetto, Sonia Volpi, Emily Pintani, Valentino Bezzerri, Marco Cipolli

Abstract read
In one paragraph

Article in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Potassium Channels of the Airway Epithelium.Acta physiologica (Oxford, England) · 2026
    Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Francesca LuccaCystic Fibrosis Center, Azienda Ospedaliera Universitaria Integrata, 37126 Verona, Italy.ORCID 0000-0002-5294-9301
Ilaria MeneghelliCystic Fibrosis Center, Azienda Ospedaliera Universitaria Integrata, 37126 Verona, Italy.
Gloria TridelloCystic Fibrosis Center, Azienda Ospedaliera Universitaria Integrata, 37126 Verona, Italy.
Francesca BuniottoCystic Fibrosis Center, Azienda Ospedaliera Universitaria Integrata, 37126 Verona, Italy.ORCID 0009-0003-1189-1144
Giulia CucchettoCystic Fibrosis Center, Azienda Ospedaliera Universitaria Integrata, 37126 Verona, Italy.
Sonia VolpiCystic Fibrosis Center, Azienda Ospedaliera Universitaria Integrata, 37126 Verona, Italy.
Emily PintaniCystic Fibrosis Center, Azienda Ospedaliera Universitaria Integrata, 37126 Verona, Italy.
Valentino BezzerriCystic Fibrosis Center, Azienda Ospedaliera Universitaria Integrata, 37126 Verona, Italy.ORCID 0000-0002-6849-4487
Marco CipolliCystic Fibrosis Center, Azienda Ospedaliera Universitaria Integrata, 37126 Verona, Italy.ORCID 0000-0001-5652-7248

Funding

Cystic Fibrosis Foundation (CFF) 005009122
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CFTR modulatorscystic fibrosisdrug safetyelexacaftorivacaftortezacaftor

Identifiers

PMID40566080
PMCPMC12194673

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.